[Surgical treatment for pulmonary tuberculosis with Mycobacterium resistance to drugs].

O N Ots, T V Agkatsev, M I Perel'man
{"title":"[Surgical treatment for pulmonary tuberculosis with Mycobacterium resistance to drugs].","authors":"O N Ots,&nbsp;T V Agkatsev,&nbsp;M I Perel'man","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>The results of surgical treatment were analyzed in 481 patients who had been preoperatively found to have drug resistance. Patients with fibrocavernous, cirrhotic tuberculosis, chronic pleural empyema, and cavernous pneumonia constituted the vast majority (83.2%). Chemotherapy was performed by individual schemes, by taking into account MBT susceptibility. Glutoxim and pentaglobin were used as pathogenetic therapy for immunity correction. Resection-type operations [n = 368 (68.9%)], thorocoplastic interventions [n = 78 (14.6%)], thoracostomy or cavernostomy [n = 35 (6.5%)], pleurectomy [n = 26 (4.9%)], operation on the stump of the main bronchus [n = 15 (2.8%)], and mediastinal lymphadenectomy [n = 12 (2.2%)] were predominant. Postoperative complications occurred in 15.5% of cases; mortality was 1.7%. The mycobacterium resistance to drugs verified by laboratory studies exerted no evident impact on the number and pattern of postoperative complications. The results of treatment depended on the extent and presence of complications of a tuberculous process, comorbidity, suppressed immunity, and the scope of a surgical intervention.</p>","PeriodicalId":85348,"journal":{"name":"Problemy tuberkuleza i boleznei legkikh","volume":" 2","pages":"42-9"},"PeriodicalIF":0.0000,"publicationDate":"2009-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Problemy tuberkuleza i boleznei legkikh","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The results of surgical treatment were analyzed in 481 patients who had been preoperatively found to have drug resistance. Patients with fibrocavernous, cirrhotic tuberculosis, chronic pleural empyema, and cavernous pneumonia constituted the vast majority (83.2%). Chemotherapy was performed by individual schemes, by taking into account MBT susceptibility. Glutoxim and pentaglobin were used as pathogenetic therapy for immunity correction. Resection-type operations [n = 368 (68.9%)], thorocoplastic interventions [n = 78 (14.6%)], thoracostomy or cavernostomy [n = 35 (6.5%)], pleurectomy [n = 26 (4.9%)], operation on the stump of the main bronchus [n = 15 (2.8%)], and mediastinal lymphadenectomy [n = 12 (2.2%)] were predominant. Postoperative complications occurred in 15.5% of cases; mortality was 1.7%. The mycobacterium resistance to drugs verified by laboratory studies exerted no evident impact on the number and pattern of postoperative complications. The results of treatment depended on the extent and presence of complications of a tuberculous process, comorbidity, suppressed immunity, and the scope of a surgical intervention.

结核分枝杆菌耐药肺结核的外科治疗。
对术前发现耐药的481例患者的手术治疗结果进行分析。纤维海绵状、肝硬化结核、慢性胸膜脓肿和海绵状肺炎患者占绝大多数(83.2%)。化疗采用个别方案,考虑到MBT的易感性。采用糖毒素和五血红蛋白作为致病药物进行免疫纠正。以切除型手术[n = 368(68.9%)]、胸廓成形术[n = 78(14.6%)]、开胸或海绵体造口术[n = 35(6.5%)]、胸膜切除术[n = 26(4.9%)]、主支气管残端手术[n = 15(2.8%)]、纵隔淋巴结切除术[n = 12(2.2%)]为主。术后并发症发生率为15.5%;死亡率为1.7%。实验室证实的分枝杆菌耐药对术后并发症的数量和模式无明显影响。治疗的结果取决于结核过程并发症的程度和存在、合并症、抑制免疫和手术干预的范围。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信